The placebo effect in cannabis trials for MS spasticity may mask real treatment benefits
In enriched design trials of THC/CBD spray for MS spasticity, the overall therapeutic gain over placebo was about 1.27 points on a 10-point scale, with carryover effects complicating interpretation.
Quick Facts
What This Study Found
This review examined the placebo response in enriched clinical trials of THC/CBD oromucosal spray (Sativex) for MS spasticity. In enriched designs, patients who respond during an initial open-label phase are randomized to continue treatment or switch to placebo.
The authors identified that placebo-allocated patients maintained some improvement after randomization, likely due to carryover effects from the enrichment phase and the pharmacological properties of cannabinoids (slow clearance). The overall therapeutic gain of THC/CBD spray over placebo was estimated at about 1.27 points on a 0-10 spasticity scale, representing a 20.1% improvement from baseline.
The review cautioned that enriched design studies for cannabinoid medications require careful interpretation, as the design itself can underestimate true treatment effects by inflating placebo responses.
Key Numbers
Overall therapeutic gain: ~1.27 points on 0-10 NRS. Improvement: ~20.1% from baseline NRS score. 16-week assessment period after enrichment. Enriched design inflated placebo responses.
How They Did This
Review of enriched design clinical trial data for THC/CBD oromucosal spray in MS spasticity. Analyzed placebo effects during enrichment and post-randomization phases, examining carryover effects and other factors maintaining efficacy in placebo-allocated patients.
Why This Research Matters
Understanding how clinical trial design affects results is essential for accurate drug evaluation. If cannabinoid trials systematically underestimate treatment effects due to enriched designs and carryover, real clinical benefits may be larger than reported.
The Bigger Picture
Clinical trials of cannabinoid medications face unique methodological challenges. Slow drug clearance, strong placebo effects for symptom-based outcomes, and the enriched design all make it difficult to capture true treatment effects, potentially leading to underestimation of efficacy.
What This Study Doesn't Tell Us
Focus on a single medication (THC/CBD spray) and one condition (MS spasticity). The estimated therapeutic gain is an aggregate that may not apply to all patients. The review discusses potential biases but cannot fully quantify them.
Questions This Raises
- ?Should cannabinoid trials use different design approaches to avoid carryover effects?
- ?Would non-enriched designs show larger treatment effects?
- ?How do placebo effects in cannabinoid trials compare to other neurological medications?
Trust & Context
- Key Stat:
- 1.27-point improvement on 10-point spasticity scale over placebo
- Evidence Grade:
- Review of enriched design trial data. Important methodological contribution but based on a single treatment and condition.
- Study Age:
- Published in 2015. Additional Sativex trials have been completed since.
- Original Title:
- Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
- Published In:
- CNS neuroscience & therapeutics, 21(3), 215-21 (2015)
- Authors:
- Di Marzo, Vincenzo(23), Centonze, Diego(4)
- Database ID:
- RTHC-00947
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does THC/CBD spray work for MS spasticity?
Clinical trials show a modest but real benefit over placebo (~1.27 points on a 10-point scale). This review argues the true benefit may be underestimated due to the trial design used.
What is an enriched clinical trial design?
Patients first try the drug openly, and only those who respond are then randomized to continue or switch to placebo. This can inflate placebo responses because patients switching from active drug may retain some benefit.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00947APA
Di Marzo, Vincenzo; Centonze, Diego. (2015). Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.. CNS neuroscience & therapeutics, 21(3), 215-21. https://doi.org/10.1111/cns.12358
MLA
Di Marzo, Vincenzo, et al. "Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.." CNS neuroscience & therapeutics, 2015. https://doi.org/10.1111/cns.12358
RethinkTHC
RethinkTHC Research Database. "Placebo effects in a multiple sclerosis spasticity enriched ..." RTHC-00947. Retrieved from https://rethinkthc.com/research/di-2015-placebo-effects-in-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.